Multidose Safety and Tolerability Study of Liposomal Amikacin for Inhalation (Arikace™) In Cystic Fibrosis Patients
This study has been completed.
Information provided by (Responsible Party):
First received: November 13, 2007
Last updated: October 6, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||June 2009|
|Primary Completion Date:||June 2009 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||September 29, 2016|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Clancy JP, Dupont L, Konstan MW, Billings J, Fustik S, Goss CH, Lymp J, Minic P, Quittner AL, Rubenstein RC, Young KR, Saiman L, Burns JL, Govan JR, Ramsey B, Gupta R; Arikace Study Group.. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax. 2013 Sep;68(9):818-25. doi: 10.1136/thoraxjnl-2012-202230.